Category Archives: Warning Letters

Warning and NOV Letter Summary – 3rd Quarter 2011

Last week it was noted that enforcement at DDMAC, newly renamed the Office of Prescription Drug Promotion (OPDP)  has slowed down.  Last quarter, the division, now an office, issued only four letters.  Not only is it worthwhile to look at … Continue reading

Posted in Warning Letters | 2 Comments

DDMAC Enforcement Trickles

For some time there has been speculation that enforcement at FDA is up.  But it should be noted that regulatory action letters come from several different parts of the agency and encompass much more than promotional communications. For our purposes, … Continue reading

Posted in Uncategorized, Warning Letters | 2 Comments

Reflections on an Abyss – the Facebook Policy Change

Remember when the calendar was turning to the year 2000 and there was a great hand-wringing going on about whether or not Y2K would bring a digital meltdown?  And then the clock ticked, and it didn’t? One was reminded of … Continue reading

Posted in FDA Policy, New and Social Media, Warning Letters | 1 Comment

Some Lessons Learned from 2011 NOV and Warning Letters

Earlier this week, we examined the Warning and NOV letters that came from FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC).  Today we’re going to look at a few of the communications lessons learned from same – and reminding … Continue reading

Posted in Warning Letters | Comments Off

Warning and NOV Letter Summary – First Quarter 2011

For a while it seemed that FDA’s DDMAC was raising the enforcement bar.  During the Bush years, enforcement plummeted from previous years dramatically.  In 2008, the numbers seemed to rise, though in 2009, the numbers were actually a bit thrown … Continue reading

Posted in Warning Letters | Comments Off